Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Dimerix Limited ( (AU:DXB) ) is now available.
Dimerix Limited announced a change in the director’s interest, specifically regarding the acquisition of unlisted options by Director Nina Webster. This change is part of the company’s Omnibus Equity Plan, reflecting strategic moves to align management interests with shareholder value. The issuance of these options, valued at $1,093,500, indicates confidence in the company’s future growth and operational strategies.
The most recent analyst rating on (AU:DXB) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
More about Dimerix Limited
Dimerix Limited operates in the biotechnology industry, focusing on developing innovative pharmaceutical products. The company is involved in creating therapies for unmet medical needs, particularly in the area of kidney disease and other inflammatory conditions.
Average Trading Volume: 1,175,581
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$345.2M
See more data about DXB stock on TipRanks’ Stock Analysis page.